Please login to the form below

Not currently logged in
Email:
Password:

advanced breast cancer

This page shows the latest advanced breast cancer news and features for those working in and with pharma, biotech and healthcare.

NICE says no to Novartis’ Kisqali combo in breast cancer

NICE says no to Novartis’ Kisqali combo in breast cancer

receptor-positive, HER2-negative, locally advanced or metastatic breast cancer who have had previous endocrine therapy. ... Kisqali, Verzenio as well as Pfizer’s market-leading CDK 4/6 inhibitor Ibrance (palbociclib) are already recommended for

Latest news

  • Lynparza set for further expansion with EU approval in breast cancer Lynparza set for further expansion with EU approval in breast cancer

    There were an estimated 2.1m new cases of breast cancer worldwide last year, and around 30% of women diagnosed with early breast cancer will go on to develop advanced disease. ... The OlympiAD trial supported the approval, and showed Lynparza produced an

  • AZ makes $6.9bn play for Daiichi Sankyo HER2 drug AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

    DS-8201) – is in very late-stage development with a regulatory filing due later this year in advanced or refractory breast cancer. ... The ADC has picked up a breakthrough designation from the FDA as treatment for advanced HER2-positive breast cancer

  • Tecentriq gains first IO approval in triple negative breast cancer Tecentriq gains first IO approval in triple negative breast cancer

    A coup for Roche in IO field dominated by Keytruda. Roche has stolen a march on market leader Keytruda by gaining the first immuno-oncology approval in triple negative breast cancer. ... Tecentriq (atezolizumab) can now be used in combination with

  • Novartis aims for 10 blockbuster launches by 2020 Novartis aims for 10 blockbuster launches by 2020

    Lutathera -Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumours. 2019. BYL719 – advanced breast cancer. ... Entresto - Heart failure with preserved ejection fraction (HFpEF). INC280 – non-small cell lung cancer.

  • Immunomedics craters after FDA rejects breast cancer ADC Immunomedics craters after FDA rejects breast cancer ADC

    Regulator wants to see more data on manufacturing. Shares in Immunomedics have gone into steep decline after the FDA rejected its breast cancer drug sacituzumab govitecan. ... review of the drug for patients with advanced triple-negative breast cancer

More from news
Approximately 1 fully matching, plus 139 partially matching documents found.

Latest Intelligence

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others. ... In October the FDA also approved Talzenna (talazoparib), a new treatment of deleterious or

  • Deal Watch January 2018

    The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... that is highly selective for HER2

  • Digital disruption Digital disruption

    Targeting advanced breast cancer the partners will combine real-world patient data and cognitive computing to ‘optimise cancer care and improve outcomes’. ... Next, they draw in the basic signalling pathways that can go wrong in cancer cells.

  • Deal Watch August 2016 Deal Watch August 2016

    The lead product is talazoparib, a PARP inhibitor, bought from BioMarin in phase III for treatment of BRCA mutated advanced breast cancer. ... This would complement Pfizer's palbococlib, launched in the US in February 2015, to treat HR+/HER2 metastatic

  • Pharma deals during July 2014 Pharma deals during July 2014

    investors. Seragon's focus is in hormone dependent cancers and specifically the development of its Selective Estrogen Receptor Degrader (SERD) platform of oral, small molecule therapeutics for breast and other cancers. ... The lead SERD compound, ARN-810,

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics